27167-53-9 Usage
Description
Z-D-ALA-OSU, also known as N-α-aminoacyl derivatives of melphalan, is an intermediate compound derived from the synthesis process of melphalan, a chemotherapeutic drug. It is a white powder with unique chemical properties that make it a valuable component in the development of targeted drug therapies.
Uses
Used in Pharmaceutical Industry:
Z-D-ALA-OSU is used as an intermediate in the preparation of N-α-aminoacyl derivatives of melphalan for potential use in drug targeting. Its role in the synthesis process is crucial, as it helps in the development of targeted therapies that can specifically deliver the chemotherapeutic agent to cancer cells, minimizing damage to healthy cells and reducing side effects.
Additionally, Z-D-ALA-OSU's chemical properties as a white powder make it suitable for various applications in the pharmaceutical industry, such as a starting material for the synthesis of other drug compounds or as a component in drug formulations.
Check Digit Verification of cas no
The CAS Registry Mumber 27167-53-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,7,1,6 and 7 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 27167-53:
(7*2)+(6*7)+(5*1)+(4*6)+(3*7)+(2*5)+(1*3)=119
119 % 10 = 9
So 27167-53-9 is a valid CAS Registry Number.
27167-53-9Relevant articles and documents
SOLUTION PHASE METHOD FOR PREPARING ETELCALCETIDE
-
Paragraph 0042; 0119, (2016/10/11)
The instant disclosure is directed to solution phase fragment coupling methods for preparing etelcalcetide and its pharmaceutically acceptable salts.
Cephalosporin prodrugs of paclitaxel for immunologically specific activation by L-49-sFv-β-lactamase fusion protein
Vrudhula, Vivekananda M.,Kerr, David E.,Siemers, Nathan O.,Dubowchik, Gene M.,Senter, Peter D.
, p. 539 - 542 (2007/10/03)
Paclitaxel conjugates of 7-phenylacetamidocephalosporanic acid were prepared as prodrugs for site specific activation by targeted β-lactamase. Immunologically specific activation of the prodrug 5 containing 3,3-dimethyl-4-amino-butyric acid as linker in combination with the fusion protein L-49-sFv-β-lactamase was demonstrated in vitro on 3677 melanoma cells.